Traws Pharma, Inc. quarterly report, Q3 FY2020

Filing summary

Issuer and period: The supplied filing is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020, not a filing identified as Traws Pharma, Inc. This issuer-name discrepancy should be verified.

Business context

Onconova is a clinical-stage oncology company with limited collaboration revenue and substantial ongoing research and development costs. Following the August 2020 Phase 3 INSPIRE trial’s failure to show a survival benefit, the company said it would not further pursue intravenous rigosertib for higher-risk MDS. It is focusing on ON 123300 and oral rigosertib programs.

Financial results and liquidity

For the nine months, revenue was down 92% from $2.15 million in 2019, primarily because 2019 included HanX rigosertib license revenue. Net loss increased from $15.76 million to $18.73 million. Quarterly net loss increased from $4.60 million to $6.24 million as operating expenses rose. Revenue was principally SymBio license-fee recognition and supply activity.

At September 30, cash and cash equivalents were $24.20 million, working capital was $15.7 million, total assets were $25.21 million, and total liabilities were $12.99 million. Current liabilities were $9.29 million. The balance sheet reports a $176,000 warrant liability; no conventional borrowings are identified in the supplied filing text. Cash increased $1.47 million over the nine months, as $19.08 million of financing cash inflows exceeded operating and investing outflows. Cash at September 30, 2019 was $4.82 million.

Material developments, outlook and risks

• INSPIRE’s intent-to-treat overall survival was 6.4 months with IV rigosertib versus 6.3 months with physician’s choice; the difference was not statistically significant (p=0.33). The company discontinued its planned IV rigosertib effort in higher-risk MDS.
• ON 123300’s China Phase 1 study began in September 2020, with the first patient enrolled September 15. The company planned a U.S. IND filing by year-end 2020 and anticipated a U.S. first-in-human study in early 2021; these were forward-looking plans, not reported outcomes.
• Management estimated that September 30 cash would fund operations and ongoing trials into the first quarter of 2022, but said substantial additional financing would be needed. It warned financing may be unavailable or dilutive and that failure to obtain funding could require curtailments or threaten continued operations.
• After the INSPIRE outcome, six employees—26% of staff—were terminated in September. The company notified its landlord in October that it would not renew its lease expiring February 2021 and was considering lower-cost space or remote work.
• Nasdaq notified the company in October 2020 that it did not meet the $1 minimum bid-price rule. The stated initial compliance deadline was April 5, 2021; delisting could impair liquidity and the ability to raise capital.
• COVID-19 had not caused a material impact identified through September 30, but the company cited potential clinical-trial, manufacturing, supply-chain and financing disruption. It reported no pending material legal proceedings and stated disclosure controls were effective.
• The 2019 HanX rigosertib agreement was deemed void in January 2020 after HanX failed to meet its obligations; rights reverted to Onconova. The 2019 comparison period included related upfront license revenue.

Most important facts to verify

1. Confirm the issuer identity: the filing names Onconova Therapeutics, Inc., whereas the request metadata names Traws Pharma, Inc.
2. Check subsequent cash use, financing and whether the stated first-quarter 2022 runway estimate remained valid.
3. Verify subsequent progress and actual regulatory status of ON 123300 and the oral rigosertib studies.
4. Review subsequent Nasdaq bid-price compliance and any reverse split or listing action.
5. Assess the dilution and share-count effects of equity offerings and warrant exercises; weighted-average shares differed substantially between 2020 and 2019.